Literature DB >> 9933104

Direct and indirect T cell priming by dendritic cell vaccines.

S Cayeux1, G Richter, C Becker, A Pezzutto, B Dörken, T Blankenstein.   

Abstract

The mechanisms by which dendritic cell (DC) vaccines prime host T cells in vivo was analyzed. Mice were immunized with syngeneic bone marrow-derived DC and as surrogate antigen beta-galactosidase (beta-gal) was used. DC either pulsed with peptide, loaded with beta-gal antigen or gene-modified induced beta-gal-specific cytotoxic T lymphocytes (CTL) and moderate rejection of an in vivo challenge with beta-gal expressing tumors. In addition, beta-gal-specific CTL lysed the syngeneic DC that were used as vaccines. Using SCID mice reconstituted with F1 lymphocytes, direct priming by gene-modified DC vaccines was demonstrated by the presence of beta-gal-specific CTL of the haplotype exclusively expressed by DC while indirect priming by host antigen-presenting cells (APC) was shown by the detection of CTL of the haplotype exclusively present on host APC and absent on DC vaccines. Since DC immunization in syngeneic mice was associated with an increase in NK1.1+/Ly49C- cells and detectable lysis of DC in vitro by lymphokine-activated killer cells, DC vaccines appear to interact with host natural killer cells as well as with antigen-specific T cells. These effector cells in turn may lyse DC vaccines thereby leading to the release of antigens that can be taken up by host APC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933104     DOI: 10.1002/(SICI)1521-4141(199901)29:01<225::AID-IMMU225>3.0.CO;2-W

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.

Authors:  C Chiodoni; P Paglia; A Stoppacciaro; M Rodolfo; M Parenza; M P Colombo
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

2.  Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product.

Authors:  Stéphanie Mercier; Hanne Gahéry-Segard; Martine Monteil; Renée Lengagne; Jean-Gérard Guillet; Marc Eloit; Caroline Denesvre
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR.

Authors:  Tianhong Wang; Qiong Jiang; Camie Chan; Kevin S Gorski; Erin McCadden; David Kardian; Drew Pardoll; Katharine A Whartenby
Journal:  Blood       Date:  2009-01-22       Impact factor: 22.113

Review 4.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

5.  Major histocompatibility complex class II-independent generation of neutralizing antibodies against T-cell-dependent Borrelia burgdorferi antigens presented by dendritic cells: regulation by NK and gammadelta T cells.

Authors:  M L Mbow; N Zeidner; R D Gilmore; M Dolan; J Piesman; R G Titus
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells.

Authors:  X Zhang; P Zhao; C Kennedy; K Chen; J Wiegand; G Washington; L Marrero; Y Cui
Journal:  Cancer Gene Ther       Date:  2007-12-14       Impact factor: 5.987

Review 7.  Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?

Authors:  Anne Huber; Floris Dammeijer; Joachim G J V Aerts; Heleen Vroman
Journal:  Front Immunol       Date:  2018-12-03       Impact factor: 7.561

Review 8.  Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.

Authors:  Carla De Giovanni; Giordano Nicoletti; Lorena Landuzzi; Arianna Palladini; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.